Xarelto (rivaroxaban) is a blood-thinning drug (anti-coagulant) that has been linked to hundreds of injuries and deaths since it was approved in 2011.


Xarelto (rivaroxaban) is a blood-thinning drug (anticoagulant) that is used to treat blood clots, deep vein thrombosis (DVT), and pulmonary embolisms. It has been sold by Bayer HealthCare and Janssen Pharmaceuticals since 2011.

Xarelto is the second FDA-approved drug in a new generation of anticoagulants that are marketed as alternatives to Warfarin. Warfarin has been a mainstay of anti-coagulation therapy since the 1950s, but it is a problematic drug that requires frequent dosage adjustments and dietary restrictions. Unlike Warfarin, Xarelto is an easy-to-use pill taken once or twice a day.

The problem is that Xarelto has no effective reversal agent — unlike Warfarin, which can be reversed with a dose of Vitamin K. In a traumatic accident or during a cerebral hemorrhage (bleeding in the brain), doctors may struggle to stop bleeding in a patient on Xarelto. Some studies have also linked Xarelto to a higher risk of bleeding for acutely ill patients. Many lawsuits accuse drug-makers of downplaying the bleeding and blood clot risks of Xarelto.


Xarelto May Cause:

  • Uncontrollable Bleeding
  • Death due to uncontrollable bleeding
  • Brain hemorrhaging
  • Rectal bleeding
  • Intestinal bleeding

Warning Signs and Symptoms

  • Discolored urine (blood in the urine)
  • Red or black-colored stool
  • Vomiting or coughing up blood
  • Frequent nose bleeds or gum bleeding
  • Weakness and swelling in the extremities; and any other unusual bleeding

Click here for more info about Xarelto. 

Posted in News, Pharmaceutical and Medical Device Litigation.